Identification of E74-like factor 1 (ELF1) as a transcriptional regulator of the Hox cofactor MEIS1

Experimental Hematology

Volumn 38, Issue 9, 2010, Pages 798-808.e2

  Xiang, Ping ^a   Lo, Chaoyu ^a   Argiropoulos, Bob ^a   Lai, C Benjamin ^a   Rouhi, Arefeh ^a,b   Imren, Suzan ^a   Jiang, Xiaoyan ^a,c   Mager, Dixie ^a,c   Humphries R Keith, R K ^a,c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HOX PROTEIN; MYELOID ECTROPIC VIRAL INTEGRATION SITE 1 PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR ELF 1; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE MUTATION; GENETIC CONSERVATION; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; PHYLOGENY; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; UMBILICAL CORD BLOOD;

EID: 77955493246     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.06.006     Document Type: Article

References (44)

1. Spieker N., van Sluis P., Beitsma M., et al. The MEIS1 oncogene is highly expressed in neuroblastoma and amplified in cell line IMR32. Genomics 2001, 71:214-221.
2. Crijns A.P., de Graeff P., Geerts D., et al. MEIS and PBX homeobox proteins in ovarian cancer. Eur J Cancer 2007, 43:2495-2505.
3. Mercader N., Leonardo E., Azpiazu N., et al. Conserved regulation of proximodistal limb axis development by Meis1/Hth. Nature 1999, 402:425-429.
4. Argiropoulos B., Yung E., Humphries R.K. Unraveling the crucial roles of Meis1 in leukemogenesis and normal hematopoiesis. Genes Dev 2007, 21:2845-2849.
5. Winkelmann J., Schormair B., Lichtner P., et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 2007, 39:1000-1006.
6. Xiong L., Catoire H., Dion P., et al. MEIS1 intronic risk haplotype associated with restless legs syndrome affects its mRNA and protein expression levels. Hum Mol Genet 2009, 18:1065-10747.
7. Moskow J.J., Bullrich F., Huebner K., Daar I.O., Buchberg A.M. Meis1, a PBX1-related homeobox gene involved in myeloid leukemia in BXH-2 mice. Mol Cell Biol 1995, 15:5434-5443.
8. Nakamura T., Largaespada D.A., Shaughnessy J.D., Jenkins N.A., Copeland N.G. Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias. Nat Genet 1996, 12:149-153.
9. Kroon E., Krosl J., Thorsteinsdottir U., Baban S., Buchberg A.M., Sauvageau G. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J 1998, 17:3714-3725.
10. Kroon E., Thorsteinsdottir U., Mayotte N., Nakamura T., Sauvageau G. NUP98-HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice. EMBO J 2001, 20:350-361.
11. Pineault N., Buske C., Feuring-Buske M., et al. Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1. Blood 2003, 101:4529-4538.
12. Pineault N., Abramovich C., Ohta H., Humphries R.K. Differential and common leukemogenic potentials of multiple NUP98-Hox fusion proteins alone or with Meis1. Mol Cell Biol 2004, 24:1907-1917.
13. Kawagoe H., Humphries R.K., Blair A., Sutherland H.J., Hogge D.E. Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells. Leukemia 1999, 13:687-698.
14. Rozovskaia T., Feinstein E., Mor O., et al. Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4: 11) abnormality. Oncogene 2001, 20:874-878.
15. Imamura T., Morimoto A., Takanashi M., et al. Frequent co-expression of HoxA9 and Meis1 genes in infant acute lymphoblastic leukaemia with MLL rearrangement. Br J Haematol 2002, 119:119-121.
16. Wong P., Iwasaki M., Somervaille T.C., So C.W., Cleary M.L. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev 2007, 21:2762-2774.
17. Pineault N., Helgason C.D., Lawrence H.J., Humphries R.K. Differential expression of Hox, Meis1, and Pbx1 genes in primitive cells throughout murine hematopoietic ontogeny. Exp Hematol 2002, 30:49-57.
18. Hisa T., Spence S.E., Rachel R.A., et al. Hematopoietic, angiogenic and eye defects in Meis1 mutant animals. EMBO J 2004, 23:450-459.
19. Milne T.A., Martin M.E., Brock H.W., Slany R.K., Hess J.L. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res 2005, 65:11367-11374.
20. Boyer L.A., Plath K., Zeitlinger J., et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 2006, 441:349-353.
21. Esparza S.D., Chang J., Shankar D.B., Zhang B., Nelson S.F., Sakamoto K.M. CREB regulates Meis1 expression in normal and malignant hematopoietic cells. Leukemia 2008, 22:665-667.
22. Horman S.R., Velu C.S., Chaubey A., et al. Gfi1 integrates progenitor versus granulocytic transcriptional programming. Blood 2009, 113:5466-5475.
23. Hu Y.L., Fong S., Ferrell C., Largman C., Shen W.F. HOXA9 modulates its oncogenic partner Meis1 to influence normal hematopoiesis. Mol Cell Biol 2009, 29:5181-5192.
24. Matys V., Fricke E., Geffers R., et al. TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res 2003, 31:374-378.
25. Heinemeyer T., Wingender E., Reuter I., et al. Databases on transcriptional regulation: TRANSFAC, TRRD, and COMPEL. Nucleic Acids Res 1998, 26:364-370.
26. Bryne J.C., Valen E., Tang M.H., et al. JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update. Nucleic Acids Res 2008, 36(Database issue):D102-D106.
27. Li Q., Zhang M., Duan Z., Stamatoyannopoulos G. Structural analysis and mapping of DNase I hypersensitivity of HS5 of the beta-globin locus control region. Genomics 1999, 61:183-193.
28. Duan Z.J., Fang X., Rohde A., Han H., Stamatoyannopoulos G., Li Q. Developmental specificity of recruitment of TBP to the TATA box of the human gamma-globin gene. Proc Natl Acad Sci U S A 2002, 99:5509-5514.
29. Rouhi A., Gagnier L., Takei F., Mager D.L. Evidence for epigenetic maintenance of Ly49A monoallelic gene expression. J Immunol 2006, 176:2991-2999.
30. Maksakova I.A., Mager D.L. Transcriptional regulation of early transposon elements, an active family of mouse long terminal repeat retrotransposons. J Virol 2005, 79:13865-13874.
31. Mueller B.U., Pabst T. C/EBPalpha and the pathophysiology of acute myeloid leukemia. Curr Opin Hematol 2006, 13:7-14.
32. Oikawa T., Yamada T. Molecular biology of the Ets family of transcription factors. Gene 2003, 303:11-34.
33. Krivtsov A.V., Twomey D., Feng Z., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442:818-822.
34. Fukushima T., Miyazaki Y., Tsushima H., et al. The level of MEF but not ELF-1 correlates with FAB subtype of acute myeloid leukemia and is low in good prognosis cases. Leukemia Res 2003, 27:387-392.
35. Hollenhorst P.C., Shah A.A., Hopkins C., Graves B.J. Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. Genes Dev 2007, 21:1882-1894.
36. Xie X., Lu J., Kulbokas E.J., Golub T.R., et al. Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature 2005, 434:338-345.
37. Aittomäki S., Yang J., Scott E.W., Simon M.C., Silvennoinen O. Molecular basis of Stat1 and PU.1 cooperation in cytokine-induced Fcγ receptor I promoter activation. Int Immunol 2004, 16:265-274.
38. Garrett-Sinha L.A., Dahl R., Rao S., Barton K.P., Simon M.C. PU.1 exhibits partial functional redundancy with Spi-B, but not with Ets-1 or Elf-1. Blood 2001, 97:2908-2912.
39. Hollenhorst P.C., Jones D.A., Graves B.J. Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res 2004, 21:5693-5702.
40. Taub J.W., Huang X., Matherly L.H., et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood 1999, 94:1393-1400.
41. Marcucci G., Baldus C.D., Ruppert A.S., et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 2005, 23:9234-9242.
42. Stankiewicz M.J., Crispino J.D. ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells. Blood 2009, 113:3337-3347.
43. Lasa A., Carnicer M.J., Aventín A., et al. MEIS 1 expression is downregulated through promoter hypermethylation in AML1-ETO acute myeloid leukemias. Leukemia 2004, 18:1231-1237.
44. Graves B.J., Petersen J.M. Specificity within the ets family of transcription factors. Adv Cancer Res 1998, 75:1-55.